The INADcure Foundation

The Ina Dcure Foundation

Non Profit Organization Management, 12 Scott Ct, Fairfield, New Jersey, 07004, United States, 1-10 Employees

inadcure.org

  • LinkedIn

Who is THE INADCURE FOUNDATION

The INADcure Foundation, is the only U.S. based nonprofit dedicated exclusively to the INAD community. The Foundations mission is to support the development of treatments, including a cur...

Read More

map
  • 12 Scott Ct, Fairfield, New Jersey, 07004, United States Headquarters: 12 Scott Ct, Fairfield, New Jersey, 07004, United States
  • 2017 Date Founded: 2017
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Non Profit Organization Management

SIC SIC Code: 8641

checked-icon Does something look wrong? Fix it. | View contact records from THE INADCURE FOUNDATION

The INADcure Foundation Org Chart and Mapping

Employees

Leena Panwala

Co-Founder and Executive Director

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding The INADcure Foundation

Answer: The INADcure Foundation's headquarters are located at 12 Scott Ct, Fairfield, New Jersey, 07004, United States

Answer: The INADcure Foundation's official website is https://inadcure.org

Answer: The INADcure Foundation's revenue is Under $1 Million

Answer: The INADcure Foundation's SIC: 8641

Answer: The INADcure Foundation has 1-10 employees

Answer: The INADcure Foundation is in Non Profit Organization Management

Answer: The INADcure Foundation contact info: Phone number: Website: https://inadcure.org

Answer: The INADcure Foundation, is the only U.S. based nonprofit dedicated exclusively to the INAD community. The Foundations mission is to support the development of treatments, including a cure, for Infantile Neuroaxonal Dystrophy (INAD), a lysosomal storage disorder and other forms of PLA2G6-related neurodegeneration (PLAN). PLA2G6-related neurodegeneration (PLAN) is an umbrella term of three diseases caused by PLA2G6 loss. Infantile Neuroaxonal Dystrophy (INAD) is typically recognized in early childhood between the ages of 6 months and 2 years. A common pattern in young children is loss of previously acquired skills, mental and physical ability and progression of the disease over time. Atypical or Juvenile Neuroaxonal Dystrophy (aNAD) affects children at around age 4. The symptoms of individuals with aNAD are fairly stable during their early childhood but start declining between the ages of 7 and 12. A third form affects young adults who develop dystonia-parkinsonism. There is currently no cure for these diseases. We are actively forging partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new and pending treatments. In collaboration with our scientific advisors, we identify the most promising INAD research projects for partnership and funding. We work tirelessly in our efforts to fund the research that we hope will eradicate INAD, so that not one more child has to suffer from this devastating disease.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access